2. Search Result
Search Result
Results for "

α-syn

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

8

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-157308
    α-Synuclein inhibitor 10

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC50 value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .
    α-Synuclein inhibitor 10
  • HY-163145
    α-Synuclein inhibitor 11

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .
    α-Synuclein inhibitor 11
  • HY-170381
    α-syn aggregation inhibitor-1

    		α-synuclein Neurological Disease
    α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for α-syn aggregation. α-syn aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y .
    α-syn aggregation inhibitor-1
  • HY-163519
    α-Synuclein inhibitor 13

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .
    α-Synuclein inhibitor 13
  • HY-157806
    α-Synuclein inhibitor 12

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .
    α-Synuclein inhibitor 12
  • HY-149509
    α-Synuclein inhibitor 9

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
    α-Synuclein inhibitor 9
  • HY-147668
    α-Synuclein inhibitor 6

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.70 μM and inhibition ratio at 30 μM of 94.4% .
    α-Synuclein inhibitor 6
  • HY-147666
    α-Synuclein inhibitor 4

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 0.98 μM and inhibition ratio at 30 μM of 91.2% .
    α-Synuclein inhibitor 4
  • HY-147669
    α-Synuclein inhibitor 7

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.95 μM and inhibition ratio at 30 μM of 85.8% .
    α-Synuclein inhibitor 7
  • HY-147667
    α-Synuclein inhibitor 5

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3% .
    α-Synuclein inhibitor 5
  • HY-147644
    α-Synuclein inhibitor 3

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .
    α-Synuclein inhibitor 3
  • HY-168647
    KAC-50.1

    		α-synuclein Neurological Disease
    KAC-50.1 is an α-Synuclein (α-syn) PET ligand, with a KD of 35 nM toward site 2 in recombinant α-syn fibrils .
    KAC-50.1
  • HY-151554
    SQ-3

    		Amyloid-β Others
    SQ-3 is a quinoline analogue, displays moderate selectivity for α-syn aggregates (Ki=39.3 nM) over β-amyloid (Aβ) aggregates (Ki=230 nM). [ 18F]SQ3 has basic properties as a lead compound for the development of a useful α-syn imaging probe .
    SQ-3
  • HY-150209
    MODAG-001

    		Fluorescent Dye Neurological Disease
    MODAG-001 can bind to synuclein fibrils in a rat brain. MODAG-001 is a candidate α-syn imaging probe .
    MODAG-001
  • HY-157225
    Brazilin-7-acetate

    		α-synuclein Metabolic Disease
    Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .
    Brazilin-7-acetate
  • HY-163830
    Pegasus

    DAD9

    		 Dopamine Receptor Neurological Disease
    Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease .
    Pegasus
  • HY-163739
    LETC

    		α-synuclein Neurological Disease
    LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .
    LETC
  • HY-145580
    Minzasolmin

    UCB0599; (R)-NPT200-11

    		 α-synuclein Neurological Disease
    Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models .
    Minzasolmin
  • HY-17406S
    Tolcapone-d7

    Ro 40-7592 d7

    		 Isotope-Labeled Compounds COMT Amyloid-β Neurological Disease
    Tolcapone-d7 is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells .
    Tolcapone-d7
  • HY-173049
    2N4R Tau/α-Syn against-1

    		α-synuclein Neurological Disease
    2N4R Tau/α-Syn against-1 (Compound 4d) targets α-synuclein and tau protein, inhibits the fibrillation and oligomer formation of α-synuclein and tau proteins, exhibits disaggregation activity on Aβ fibers. 2N4R Tau/α-Syn against-1 can be used in research of Parkinson's disease and Alzheimer's disease .
    2N4R Tau/α-Syn against-1
  • HY-163987
    SIRT3 activator 2

    		Sirtuin Neurological Disease
    SIRT3 activator 2 (compound 2a) is a SIRT3 activator. SIRT3 activator 2 improved the thermal stability of SIRT3 in SH-SY5Y cells, indicating that it can directly bind to SIRT3, has SIRT3 dependency in SH-SY5Y to clear α-Syn. SIRT3 activator 2 improves motor function in Parkinson mice, preventing Parkinson (DA) neuron loss in the substantia nigra in a dose-dependent manner .
    SIRT3 activator 2
  • HY-149065
    D-685

    		α-synuclein Neurological Disease
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration .
    D-685
  • HY-139830
    Dyrk1A-IN-1

    		DYRK Neurological Disease
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-139307
    MG-2119

    		Tau Protein Neurological Disease
    MG-2119 is a potent monomeric tau and α-syn aggregation inhibitor. MG-2119 is a potential agent for neurological disorders research .
    MG-2119
  • HY-N10306
    Sycosterol A

    		α-synuclein Neurological Disease
    Sycosterol A is a sterol-based α-synuclein (α-syn) inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .
    Sycosterol A
  • HY-N0901A
    Corynoxine B
    3 Publications Verification

    		 α-synuclein Neurological Disease Cancer
    Corynoxine B is an alkaloid-based autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .
    Corynoxine B
  • HY-169198
    GSD-16-24

    		α-synuclein Neurological Disease
    GSD-16-24 is a lead compound that binds directly to the C-terminal IDR of α-syn monomers and fibrils, thereby preventing fibrils from binding to the receptor. GSD-16-24 can be used in Parkinson's research .
    GSD-16-24
  • HY-130398
    Aerophobin-2

    		α-synuclein Neurological Disease
    Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .
    Aerophobin-2
  • HY-170553
    ZPD-2

    		α-synuclein Neurological Disease
    ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .
    ZPD-2
  • HY-161328
    MAO-B-IN-31

    		α-synuclein Neurological Disease
    MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC50 value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .
    MAO-B-IN-31
  • HY-159945
    tau Protein/α-synuclein-IN-2

    		α-synuclein Neurological Disease
    Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.
    tau Protein/α-synuclein-IN-2
  • HY-17406
    Tolcapone
    2 Publications Verification

    Ro 40-7592

    		 COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone
  • HY-156435
    tau Protein/α-synuclein-IN-1

    		α-synuclein Neurological Disease
    tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein-IN-1 can be used in study Alzheimer’s disease .
    tau Protein/α-synuclein-IN-1
  • HY-N15255
    5-S-Cysteinyldopamine

    Cysdopamine; 5-S-CyS-DA

    		 α-synuclein Neurological Disease
    5-S-Cysteinyldopamine is a sulfur ether metabolite of dopamine that can induce neurodegeneration by inducing widespread oxidative stress and protein aggregation, characterized by protein carbonylation and glutathione depletion, and upregulating the expression of α-Syn and ERp57 proteins. 5-S-Cysteinyldopamine can be used in the study of neurodegenerative diseases, such as Parkinson's disease .
    5-S-Cysteinyldopamine
  • HY-N0901AR
    Corynoxine B (Standard)

    		α-synuclein Neurological Disease Cancer
    Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .
    Corynoxine B (Standard)
  • HY-157700
    Hexadecenyl-2-hydroxy-sn-glycero-3-PC

    C16(Plasm) LPC; Lysophosphatidylcholine 16:0p/0:0

    		 Biochemical Assay Reagents Neurological Disease
    Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. Hexadecenyl-2-hydroxy-sn-glycero-3-PC prolongs the lag-phase of α-syn aggregation, and can be used in Parkinson’s disease research .
    Hexadecenyl-2-hydroxy-sn-glycero-3-PC
  • HY-17406S1
    Tolcapone-d4

    Ro 40-7592-d4

    		 Isotope-Labeled Compounds COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone-d4 is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773?nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone-d4
  • HY-159941
    tau-0N4R-IN-1

    		α-synuclein Neurological Disease
    tau-0N4R-IN-1 (Compound 6T) is an BBB-penetrable inhibitor of tau 0N4R oligomerization. tau-0N4R-IN-1 effectively inhibits the fibrosis of tau 0N4R, 2N3R, and 2N4R, exhibits an anti-seeding effect on tau in vitro, reduces the oligomerization of α-syn dose-dependently, and prevents formation of α-syn inclusions. tau-0N4R-IN-1 is stable in mouse microsomes and reduces Aβ plaques in brain tissues from AD patients. tau-0N4R-IN-1 has good pharmacokinetic properties in mice .
    tau-0N4R-IN-1
  • HY-17406R
    Tolcapone (Standard)

    Ro 40-7592 (Standard)

    		 COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Standard) is the analytical standard of Tolcapone. This product is intended for research and analytical applications. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone (Standard)
  • HY-101855
    Emrusolmin

    Anle138b

    		 Amyloid-β Neurological Disease
    Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
    Emrusolmin
  • HY-153169
    6PPD-Q
    1 Publications Verification

    6PPD-Quinone

    		 α-synuclein Others
    6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .
    6PPD-Q
  • HY-W042156
    Aegeline

    		Fungal Neurological Disease
    Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .
    Aegeline
  • HY-W042156R
    Aegeline (Standard)

    		Fungal Neurological Disease
    Aegeline (Standard) is the analytical standard of Aegeline. This product is intended for research and analytical applications. Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .
    Aegeline (Standard)
  • HY-110174
    NAB2

    		α-synuclein Neurological Disease
    NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease .
    NAB2
  • HY-16009
    Buntanetap

    (+)-Phenserine; ANVS401

    		 α-synuclein Neurological Disease Inflammation/Immunology
    Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
    Buntanetap
  • HY-16009B
    Buntanetap L-Tartrate

    (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate

    		 Amyloid-β Neurological Disease
    Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC50 = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
    Buntanetap L-Tartrate
  • HY-120722
    TCH-165
    1 Publications Verification

    		 Proteasome Cancer
    TCH-165 is a small molecule modulator of proteasome assembly, which increases 20S levels and facilitates 20S-mediated protein degradation .
    TCH-165
  • HY-123439
    FTY720-C2

    		Others Neurological Disease
    FTY720-C2 is a derivative of FTY72 (HY-12005). FTY720-C2 promotes the expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in multiple system atrophy (MSA) models, without causing immunosuppression. FTY720-C2 improves motor dysfunction and reduces the levels of insoluble alpha-synuclein (αSyn) in MSA mouse models. FTY720-C2 is blood-brain barrier penetrate .
    FTY720-C2
  • HY-162363
    MD6a

    		PARP Neurological Disease
    MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect .
    MD6a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: